EGFR and colorectal neoplasm: In this situation, it is clear that the only evaluation of KRAS mutation status in primary colorectal tumor may be inadequate to predict response to anti-EGFR therapy of the corresponding CRLM and may provide limited information prior to multimodal treatment.